SEARCH OUR PAGES

Autoimmune Diseases

Autoimmune Diseases

Autoimmune Diseases Pipeline

OSE Immunotherapeutics’ autoimmune diseases pipeline consists of two clinical-stage programs with promising candidates focusing on two different pathways: the CD28 pathway with FR104 and the IL7 pathway with OSE-127.

OSE-127 is partnered with Servier for its development in ulcerative colitis and Sjögren syndrome.

Program
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Partners
AUTO-IMMUNE DESEASES
FR104
CD-28
Auto-immune diseases & Transplantation
Phase 2 planning ongoing
OSE-127
IL-7 R
UC Sjögren
Positive Phase 1 results Q4 2019
Initiation Q4 2020

Program

  • Indication Auto-immune diseases & Transplantation
  • Pre-Clinical POC
  • Phase 1
  • Phase 2 Phase 2 planning ongoing
  • Phase 3
  • Partners
  • Indication UC Sjögren
  • Pre-Clinical POC
  • Phase 1 Positive Phase 1 results Q4 2019
  • Phase 2 Initiation Q4 2020
  • Phase 3
  • Partners
  • OSE-127

    +
  • FR104

    +